Trius Therapeutics announces positive phase II results on TR-701

Published: 2009-06-12 06:59:00

Updated: 2009-06-12 06:59:00

Trius Therapeutics, Dong-A Pharmaceutical’s U.S. partner announced on June 10 that it gained the positive results from its Phase 2 clinical trial evaluating the safety and efficacy of oral TR-701, its investigational antibiotic for the treatment of severe complicated skin and skin structure infec...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK